Castle Biosciences (CSTL) Depreciation & Amortization (CF) (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 86.8% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (down 64.79% YoY) and the FY2025 annual result came in at $40.8 million, up 154.87% from the prior year.
• Depreciation & Amortization (CF) rose to $3.9 million in Q1 2026 per CSTL's latest filing, from $3.8 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $29.8 million in Q1 2025, with the low at $2.2 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $4.9 million, with a median of $3.3 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) jumped 823.18% in 2022 and tumbled 86.8% in 2026.
• Castle Biosciences' Depreciation & Amortization (CF) stood at $2.8 million in 2022, then grew by 13.48% to $3.2 million in 2023, then surged by 78.91% to $5.8 million in 2024, then sank by 34.52% to $3.8 million in 2025, then grew by 4.02% to $3.9 million in 2026.
• Business Quant data shows CSTL's Depreciation & Amortization (CF) at $3.9 million in Q1 2026, $3.8 million in Q4 2025, and $3.8 million in Q3 2025.